Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | IMP (inosine 5'-monophosphate) dehydrogenase 2 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Leishmania major | inosine-5-monophosphate dehydrogenase | 0.0095 | 1 | 0.5 |
Mycobacterium ulcerans | inosine 5'-monophosphate dehydrogenase | 0.0095 | 1 | 1 |
Mycobacterium ulcerans | inosine 5-monophosphate dehydrogenase | 0.0089 | 0.8869 | 0.8869 |
Mycobacterium leprae | Probable inosine-5'-monophosphate dehydrogenase GuaB2 (IMP dehydrogenase) (IMPDH) (IMPD) | 0.0095 | 1 | 1 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Echinococcus multilocularis | inosine 5' monophosphate dehydrogenase 2 | 0.0095 | 1 | 1 |
Mycobacterium tuberculosis | Probable inosine-5'-monophosphate dehydrogenase GuaB2 (imp dehydrogenase) (inosinic acid dehydrogenase) (inosinate dehydrogenase | 0.0095 | 1 | 1 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Schistosoma mansoni | inosine-5-monophosphate dehydrogenase | 0.0095 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | IMP dehydrogenase | 0.0095 | 1 | 0.5 |
Loa Loa (eye worm) | IMP dehydrogenase 1 | 0.0095 | 1 | 1 |
Echinococcus granulosus | inosine 5' monophosphate dehydrogenase 2 | 0.0095 | 1 | 1 |
Trypanosoma cruzi | GMP reductase | 0.0095 | 1 | 0.5 |
Plasmodium falciparum | inosine-5'-monophosphate dehydrogenase | 0.0089 | 0.8869 | 0.5 |
Trypanosoma brucei | inosine-5'-monophosphate dehydrogenase | 0.0095 | 1 | 0.5 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | Neuropeptide F receptor homolog | 0.0074 | 0.5801 | 0.5 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0095 | 1 | 0.5 |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0095 | 1 | 0.5 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Trypanosoma cruzi | inosine-5'-monophosphate dehydrogenase, putative | 0.0095 | 1 | 0.5 |
Plasmodium vivax | inosine-5'-monophosphate dehydrogenase, putative | 0.0089 | 0.8869 | 0.5 |
Leishmania major | guanosine monophosphate reductase | 0.0095 | 1 | 0.5 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Trypanosoma cruzi | GMP reductase | 0.0095 | 1 | 0.5 |
Onchocerca volvulus | Dopamine\/Ecdysteroid receptor homolog | 0.0074 | 0.5801 | 0.5 |
Trypanosoma brucei | GMP reductase | 0.0095 | 1 | 0.5 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Toxoplasma gondii | IMP dehydrogenas | 0.0095 | 1 | 0.5 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 | |
Mycobacterium leprae | Probable inosine-5'-monophosphate dehydrogenase GuaB3 (IMP dehydrogenase 2) (inosinic acid dehydrogenase) (inosinate dehydrogena | 0.005 | 0.0954 | 0.0954 |
Onchocerca volvulus | 0.0074 | 0.5801 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.0693 uM | Inhibition of human recombinant inosine monophosphate dehydrogenase type II . | ChEMBL. | 8863796 |
IC50 (binding) | = 0.0693 uM | Inhibition of human recombinant inosine monophosphate dehydrogenase type II . | ChEMBL. | 8863796 |
IC50 (functional) | = 0.36 uM | Inhibition of human Lymphocyte proliferation. The IC50 values were determined by interpolation using cubic spline determination. | ChEMBL. | 8863796 |
IC50 (functional) | = 0.36 uM | Inhibition of human Lymphocyte proliferation. The IC50 values were determined by interpolation using cubic spline determination. | ChEMBL. | 8863796 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 8863796 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.